|
1
|
Nasim F, Sabath BF and Eapen GA: Lung
cancer. Med Clin North Am. 103:463–473. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mao Y, Yang D, He J and Krasna MJ:
Epidemiology of lung cancer. Surg Oncol Clin N Am. 25:439–445.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Dimitrakopoulos FD, Antonacopoulou AG,
Kottorou AE, Maroussi S, Panagopoulos N, Koukourikou I, Scopa C,
Kalofonou M, Koutras A, Makatsoris T, et al: NF-kB2 genetic
variations are significantly associated with non-small cell lung
cancer risk and overall survival. Sci Rep. 8(5259)2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Feng S, Zhai J, Lu D, Lin J, Dong X, Liu
X, Wu H, Roden AC, Brandi G, Tavolari S, et al: TUSC3 accelerates
cancer growth and induces epithelial-mesenchymal transition by
upregulating claudin-1 in non-small-cell lung cancer cells. Exp
Cell Res. 373:44–56. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sahin S, Batur S, Aydin O, Ozturk T, Turna
A and Oz B: Programmed death-ligand-1 expression in non-small cell
lung cancer and prognosis. Balkan Med J. 36:184–189.
2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wu KL, Tsai YM, Lien CT, Kuo PL and Hung
AJ: The roles of MicroRNA in lung cancer. Int J Mol Sci.
20(1611)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Liu S, Yang Y, Jiang S, Tang N, Tian J,
Ponnusamy M, Tariq MA, Lian Z, Xin H and Yu T: Understanding the
role of non-coding RNA (ncRNA) in stent restenosis.
Atherosclerosis. 272:153–161. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Palomer X, Pizarro-Delgado J and
Vazquez-Carrera M: Emerging actors in diabetic cardiomyopathy:
Heartbreaker biomarkers or therapeutic targets? Trends Pharmacol
Sci. 39:452–467. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wang J, Liu H and Li M: Downregulation of
miR-505 promotes cell proliferation, migration and invasion, and
predicts poor prognosis in breast cancer. Oncol Lett. 18:247–254.
2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhang S, Zhang R, Xu R, Shang J, He H and
Yang Q: MicroRNA-574-5p in gastric cancer cells promotes
angiogenesis by targeting protein tyrosine phosphatase non-receptor
type 3 (PTPN3). Gene. 733(144383)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Vosa U, Vooder T, Kolde R, Fischer K, Valk
K, Tonisson N, Roosipuu R, Vilo J, Metspalu A and Annilo T:
Identification of miR-374a as a prognostic marker for survival in
patients with early-stage nonsmall cell lung cancer. Genes
Chromosomes Cancer. 50:812–822. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Cai K, Li HX, Li PP, Guo ZJ and Yang Y:
MicroRNA-449b-3p inhibits epithelial-mesenchymal transition by
targeting IL-6 and through the JAK2/STAT3 signaling pathway in
non-small cell lung cancer. Exp Ther Med. 19:2527–2534.
2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Cai T, Long J, Wang H, Liu W and Zhang Y:
Identification and characterization of miR-96, a potential
biomarker of NSCLC, through bioinformatic analysis. Oncol Rep.
38:1213–1223. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhu J, Zeng Y, Xu C, Qin H, Lei Z, Shen D,
Liu Z and Huang JA: Expression profile analysis of microRNAs and
downregulated miR-486-5p and miR-30a-5p in non-small cell lung
cancer. Oncol Rep. 34:1779–1786. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Liu Z, Zhang J, Gao J and Li Y:
MicroRNA-4728 mediated regulation of MAPK oncogenic signaling in
papillary thyroid carcinoma. Saudi J Biol Sci. 25:986–990.
2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Li H, Zhou X, Zhu J, Cheng W, Zhu W, Shu Y
and Liu P: MiR-4728-3p could act as a marker of HER2 status. Cancer
Biomark. 15:807–814. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Osmani L, Askin F, Gabrielson E and Li QK:
Current WHO guidelines and the critical role of immunohistochemical
markers in the subclassification of non-small cell lung carcinoma
(NSCLC): Moving from targeted therapy to immunotherapy. Semin
Cancer Biol. 52:103–109. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Singletary SE, Allred C, Ashley P, Bassett
LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, et
al: Staging system for breast cancer: Revisions for the 6th edition
of the AJCC cancer staging manual. Surg Clin North Am. 83:803–819.
2003.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hall RD, Gray JE and Chiappori AA: Beyond
the standard of care: A review of novel immunotherapy trials for
the treatment of lung cancer. Cancer Control. 20:22–31.
2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Walters S, Maringe C, Coleman MP, Peake
MD, Butler J, Young N, Bergstrom S, Hanna L, Jakobsen E, Kölbeck K,
et al: Lung cancer survival and stage at diagnosis in Australia,
Canada, Denmark, Norway, Sweden and the UK: A population-based
study, 2004-2007. Thorax. 68:551–564. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wei F, Wang M, Li Z, Wang Y and Zhou Y:
MiR593 inhibits proliferation and invasion and promotes apoptosis
in non-small cell lung cancer cells by targeting SLUG-associated
signaling pathways. Mol Med Rep. 20:5172–5182. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Yang D, Li JS, Xu QY, Xia T and Xia JH:
Inhibitory Effect of MiR-449b on cancer cell growth and invasion
through LGR4 in non-small-cell lung carcinoma. Curr Med Sci.
38:582–589. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tang X, Ding Y, Wang X, Zhao L and Bi H:
MiR-650 promotes non-small cell lung cancer cell proliferation and
invasion by targeting ING4 through Wnt-1/β-catenin pathway. Oncol
Lett. 18:4621–4628. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
He S, Liao B, Deng Y, Su C, Tuo J, Liu J,
Yao S and Xu L: MiR-216b inhibits cell proliferation by targeting
FOXM1 in cervical cancer cells and is associated with better
prognosis. BMC Cancer. 17(673)2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Bi CW, Zhang GY, Bai Y, Zhao B and Yang H:
Increased expression of miR-153 predicts poor prognosis for
patients with prostate cancer. Medicine (Baltimore).
98(e16705)2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Schmitt DC, Madeira da Silva L, Zhang W,
Liu Z, Arora R, Lim S, Schuler AM, McClellan S, Andrews JF, Kahn
AG, et al: ErbB2-intronic microRNA-4728: A novel tumor suppressor
and antagonist of oncogenic MAPK signaling. Cell Death Dis.
6(e1742)2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Newie I, Sokilde R, Persson H, Grabau D,
Rego N, Kvist A, von Stedingk K, Axelson H, Borg A,
Vallon-Christersson J and Rovira C: The HER2-encoded miR-4728-3p
regulates ESR1 through a non-canonical internal seed interaction.
PLoS One. 9(e97200)2014.PubMed/NCBI View Article : Google Scholar
|
